FDA updates/approvals
monarchE trial: Abemaciclib in the adjuvant setting of HR-positive breast cancer
Oncologyme
/ Apr 30, 2023
In the preplanned interim analysis of #monarchE trial, the addition of #abemaciclib to adjuvant endocrine therapy improved the invasive disease-free...
New FDA approval for Pembrolizumab in the adjuvant treatment of NSCLC.
Oncologyme
/ Apr 30, 2023
On January 26, 2023, the #FDA has approved #pembrolizumab for adjuvant treatment of NSCLC patients following complete resection and platinum-based...
Sodium Thiosulfate FDA apporval to reduce the risk of Ototoxicity associated with Cisplatin in Pediatric patients
Oncologyme
/ Mar 26, 2023
On September 20, 2022, the #FDA approved #sodium_thiosulfate to reduce the risk of #ototoxicity associated with #cisplatin in pediatric patients...
TOPAZ-1 trial
Oncologyme
/ Feb 15, 2023
The FDA has approved #durvalumab (Imfinzi) in combination with gemcitabine and cisplatin in adult patients with locally advanced or metastatic...
Trastuzumab deruxtecan FDA approval in metastatic NSCLC
Oncologyme
/ Mar 26, 2023
On August 11, 2022, the FDA approved #fam-trastuzumab deruxtecan-nxki (5.4 mg/kg IV every 3 weeks) for adult patients with have...
.png)
Latest Articles
- 1
- 2